AstraZeneca and Oracle Health and Life Sciences have announced a collaboration to test artificial intelligence tools for clinical trial recruitment, earlier diagnosis and drug safety monitoring, beginning with a hypertension program in Abu Dhabi.
The companies signed a nonbinding term sheet and did not disclose financial terms. Each proposed project will undergo separate review before proceeding, with legal, privacy, regulatory, ethical and institutional safeguards required.
The collaboration will combine AstraZeneca’s scientific, clinical development and regulatory expertise with Oracle’s real-world data, cloud infrastructure and AI-enabled clinical systems.
Initial projects will examine ways to connect research findings with clinical workflows, match patients to trials and generate evidence about medicines throughout their development and use. The companies also plan to explore support for care consistent with clinical guidelines.
Programs will cover cancer; cardiovascular, kidney and metabolic diseases; respiratory and immune conditions; and rare diseases. Planned regions include the United States, the Middle East and Europe, with projects involving local governments and operating under applicable regulations.
The first program, involving healthcare company M42, will focus on identifying patients with uncontrolled hypertension in Abu Dhabi, supporting treatment decisions and improving recruitment into clinical studies.
The companies said they will use deidentified real-world data under governance, privacy and security arrangements. AstraZeneca will not receive information that identifies individual patients.
AstraZeneca Chief Executive Pascal Soriot said the work would connect drug research with patient care. Oracle Chief Executive Mike Sicilia said the companies would examine how healthcare data could support research and trial access. The announcement provided no project timelines or performance targets.